Stimolazione intermittente del Theta-Burst per migliorare i sintomi negativi e la cognizione nella schizofrenia (ITBS-NKS-2024)
Stimolazione intermittente del burst Theta per i sintomi negativi e la capacità cognitiva della schizofrenia
The planned randomized, sham-controlled, double-blind, monocentric study aims to evaluate the effectiveness of intermittent Theta-Burst Stimulation (iTBS) on negative symptoms and cognitive deficits in schizophrenia. Both the cerebellar vermis and the left dorsolateral prefrontal cortex will be stimulated successively within the same session.
The goal of this trial is to learn if intermittent theta-burst stimulation (iTBS) of the cerebellum and the left dorsolateral prefrontal cortext (DLPFC) can treat negative symptoms and improve cognition in patients with schizophrenia. The main question it aims to answer is:
Does iTBS of the cerebellum and the left DLPFC improve negative symptoms in patients with schizophrenia? Researchers will compare iTBS to sham stimulation to see if iTBS improves negative symptoms.
Participants will:
- Receive 10 sessions of iTBS over the course of 2 weeks
- Undergo extensive examination before iTBS treatment, immediately after iTBS treatment and 4 weeks after iTBS treatment. The examination includes assessment of negative symptoms; psychometric assessment of cognition, social cognition, depressive symptoms; functional magnetic resonance imaging; assessment of eye movements; blood and saliva sampling; assessment of adverse events and stimulation associated sensations.
The study thus seeks to determine whether iTBS of the fronto-cerebellar network might improve negative symptoms and cognition by altering the network's functional activity. Additionally, it will investigate whether a pro-inflammatory cytokine profile could affect iTBS outcomes and whether inflammatory markers could be affected by iTBS.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Rasmus Schülke, MD (Dr. med.)
- Numero di telefono: +49 511 532 2039
- Email: schuelke.rasmus@mh-hannover.de
Luoghi di studio
-
-
Lower Saxony
-
Hanover, Lower Saxony, Germania, 30625
- Reclutamento
- Hannover Medical School
-
Contatto:
- Rasmus Schülke, MD (Dr. med.)
- Numero di telefono: +49 511 532 2039
- Email: schuelke.rasmus@mh-hannover.de
-
Investigatore principale:
- Rasmus Schülke, MD (Dr. med.)
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Diagnosis of schizophrenia (ICD-10: F20.-)
- Age: 18-65 years
- Ability to give informed consent
- Signed informed consent form
Exclusion Criteria:
- Any electronic implants
- Non-MRI-compatible metal implants (e.g., pacemaker, cochlear implant, insulin pump, metal fragment injuries, work in the metal-processing industry)
- Non-TMS-compatible metal implants (compatible items include: earrings, piercings, dental fillings, crowns, implants)
- Claustrophobia
- Epilepsy
- History of traumatic brain injury within the last 3 months
- History of stroke
- Active central nervous system (CNS) infection
- History of CNS infection within the last 3 months
- Pregnancy
- Current drug, medication, or alcohol abuse
- Simultaneous participation in another clinical trial
- Planned changes in psychopharmacological medication within the next 2 weeks
- Severe physical illnesses that could endanger the patient, affect the examinations or make the MRI scanning cause additional burden
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: iTBS
Active intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex |
Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex |
|
Comparatore fittizio: Sham iTBS
Sham intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex |
Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in negative symptoms
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points. |
From enrollment to the end of iTBS treatment
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in negative symptoms at 4-week follow-up
Lasso di tempo: From enrollment to follow-up 4 weeks after the end of iTBS treatment
|
Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points. |
From enrollment to follow-up 4 weeks after the end of iTBS treatment
|
|
Speech-gesture rating task
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Accuracy and speed of evaluations in the Speech-Gesture Rating Task. |
From enrollment to the end of iTBS treatment
|
|
Speech-gesture rating task at 4-week follow-up
Lasso di tempo: From enrollment to follow-up 4 weeks after the end of iTBS treatment
|
Accuracy and speed of evaluations in the Speech-Gesture Rating Task at 4-week follow-up. |
From enrollment to follow-up 4 weeks after the end of iTBS treatment
|
|
Eye-Tracking Task
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Changes in eye movements in the Eye-Tracking Task. |
From enrollment to the end of iTBS treatment
|
|
Eye-Tracking Task at 4-week follow-up
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS treatment
|
Changes in eye movements in the Eye-Tracking Task at 4-week follow-up. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Reading the Mind in the Eyes Test
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS treatment
|
Reading the Mind in the Eyes Test. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Reading the Mind in the Eyes Test at 4-week follow-up
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS treatment
|
Reading the Mind in the Eyes Test at 4-week follow-up. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
N-Back Test
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Working memory performance in the N-Back Test (sensitivity index). |
From enrollment to the end of iTBS treatment
|
|
N-Back Test at 4-week follow-up
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Working memory performance in the N-Back Test (sensitivity index) 4 weeks after the end of iTBS treatment. |
From enrollment to the end of iTBS treatment
|
|
FMRI: Resting-state functional connectivity
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC. |
From enrollment to the end of iTBS treatment
|
|
FMRI: Resting-state functional connectivity at 4-week follow-up
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS treatment
|
Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
FMRI: Task-related functional connectivity
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task. |
From enrollment to the end of iTBS treatment
|
|
FMRI: Task-related functional connectivity at 4-week follow-up
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS treatment
|
Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Inflammatory cytokines
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva. |
From enrollment to the end of iTBS treatment
|
|
Inflammatory cytokines at 4-week follow-up
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS treatment
|
Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Stimulation-associated perceptions
Lasso di tempo: From the beginning of each iTBS stimulation to after the end of each iTBS stimulation
|
Stimulation-associated perceptions, measured using the TMS Adverse Events and Associated Sensations Questionnaire (TMSensQ, Section IV), after each iTBS session. |
From the beginning of each iTBS stimulation to after the end of each iTBS stimulation
|
|
Therapy dropout rate
Lasso di tempo: From the beginning of iTBS treatment to the end of iTBS treatment
|
Therapy dropout rate (i.e. study termination). |
From the beginning of iTBS treatment to the end of iTBS treatment
|
|
Serious Adverse Events (SAEs)
Lasso di tempo: From the beginning of iTBS treatment to the end of iTBS treatment
|
Serious Adverse Events (SAEs), measured using TMSensQ (Section V). |
From the beginning of iTBS treatment to the end of iTBS treatment
|
|
Self-reported depression: BDI-II
Lasso di tempo: From enrollment to the end of iTBS-treatment
|
Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points. |
From enrollment to the end of iTBS-treatment
|
|
Self-reported depression at 4-week follow-up: BDI-II
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS-treatment
|
Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points. |
From enrollment to 4 weeks after the end of iTBS-treatment
|
|
Self-rated gesture perception and production: BAG
Lasso di tempo: From enrollment to the end of iTBS-treatment
|
Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points. |
From enrollment to the end of iTBS-treatment
|
|
Self-rated gesture perception and production at 4-week follow-up: BAG
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS-treatment
|
Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points. |
From enrollment to 4 weeks after the end of iTBS-treatment
|
|
Epigenetic changes of neurotrophic and immunological factors
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors. |
From enrollment to the end of iTBS treatment
|
|
Epigenetic changes of neurotrophic and immunological factors at 4-week follow-up
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS treatment
|
Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Concentrations of markers of neuronal damage
Lasso di tempo: From enrollment to the end of iTBS treatment
|
Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum. |
From enrollment to the end of iTBS treatment
|
|
Concentrations of markers of neuronal damage at 4-week follow-up
Lasso di tempo: From enrollment to 4 weeks after the end of iTBS treatment
|
Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum. |
From enrollment to 4 weeks after the end of iTBS treatment
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Rasmus Schülke, MD (Dr. med.), Hannover Medical School
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 11473_BO_S_2024
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Whether IPD may be shared has not yet been decided. IPD might not be shared due to data protection laws.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .